Smith+Nephew has inked a distribution agreement with SI Bone for the iFuse TORQ portfolio.
The portfolio includes two implants with indications for pelvic fracture fixation and fusion of the SI joint, according to a Feb. 23 news release from Smith+Nephew.
The iFuse TORQ TNT has received the FDA’s breakthrough device designation and is eligible for a Medicare New Technology Add-on Payment.
The partnership expands access to differentiated products, deepens surgeon engagement and drives growth, according to Scott Gunn, vice president trauma, extremities and shoulder at Smith+Nephew.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
